Chin-Ho Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/899722/publications.pdf

Version: 2024-02-01

96 papers	3,889 citations	94269 37 h-index	138251 58 g-index
96 all docs	96 docs citations	96 times ranked	3557 citing authors

#	Article	IF	Citations
1	Iridoids and sesquiterpenoids from Valeriana jatamansi and their anti-influenza virus activities. Bioorganic Chemistry, 2022, 121, 105692.	2.0	9
2	Anti-HIV Tigliane-Type Diterpenoids from the Aerial Parts of Wikstroemia lichiangensis. Journal of Natural Products, 2022, 85, 1658-1664.	1.5	4
3	Design, synthesis, and evaluation of â€œdual-siteâ€•binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2021, 211, 113063.	2.6	15
4	Design, synthesis, and structure activity relationship analysis of new betulinic acid derivatives as potent HIV inhibitors. European Journal of Medicinal Chemistry, 2021, 215, 113287.	2.6	20
5	Hyperdioxanes, dibenzo-1,4-dioxane derivatives from the roots of Hypericum ascyron. Journal of Natural Medicines, 2021, 75, 907-914.	1.1	4
6	Identification of anti-HIV macrocyclic daphnane orthoesters from Wikstroemia ligustrina by LCâ€“MS analysis and phytochemical investigation. Journal of Natural Medicines, 2021, 75, 1058-1066.	1.1	9
7	Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors. Current Medicinal Chemistry, 2021, 28, 4995-5003.	1.2	4
8	LC-MS Identification, Isolation, and Structural Elucidation of Anti-HIV Tigliane Diterpenoids from Wikstroemia lamatsoensis. Journal of Natural Products, 2021, 84, 2366-2373.	1.5	10
9	New phorbol ester derivatives as potent anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2021, 50, 128319.	1.0	5
10	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116414.	1.4	4
11	Daphneodorins Aâ€“C, Anti-HIV Gnidimacrin Related Macrocyclic Daphnane Orthoesters from Daphne odora. Organic Letters, 2020, 22, 11-15.	2.4	30
12	Rapid Recognition and Targeted Isolation of Anti-HIV Daphnane Diterpenes from Daphne genkwa Guided by UPLC-MSn. Journal of Natural Products, 2020, 83, 134-141.	1.5	18
13	Carbazole Alkaloids from Clausena anisum-olens: Isolation, Characterization, and Anti-HIV Evaluation. Molecules, 2020, 25, 99.	1.7	20
14	Isolation, Structural Elucidation, and Anti-HIV Activity of Daphnane Diterpenoids from Daphne odora. Journal of Natural Products, 2020, 83, 3270-3277.	1.5	16
15	Paliasanines Aâ€“E, 3,4-Methylenedioxyquinoline Alkaloids Fused with a Phenyl-14-oxabicyclo[3.2.1]octane Unit from Melochia umbellata var. deglabrata. Journal of Natural Products, 2020, 83, 2931-2939.	1.5	5
16	Novel Betulinic Acidâ€“Nucleoside Hybrids with Potent Anti-HIV Activity. ACS Medicinal Chemistry Letters, 2020, 11, 2290-2293.	1.3	18
17	Anti-HIV Tigliane Diterpenoids from Wikstroemia scytophylla. Journal of Natural Products, 2020, 83, 3584-3590.	1.5	17
18	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	1.0	3

#	Article	IF	Citations
19	Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. European Journal of Medicinal Chemistry, 2020, 190, 112085.	2.6	65
20	Anti-HIV tigliane diterpenoids from Reutealis trisperma. Phytochemistry, 2020, 174, 112360.	1.4	15
21	Bioactive ent-isopimarane diterpenoids from Euphorbia neriifolia. Phytochemistry, 2020, 175, 112373.	1.4	21
22	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	2.9	41
23	Synthesis and Structureâ€“Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents. Journal of Medicinal Chemistry, 2019, 62, 6958-6971.	2.9	17
24	Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. European Journal of Medicinal Chemistry, 2019, 183, 111696.	2.6	26
25	Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata. Journal of Natural Products, 2019, 82, 1587-1592.	1.5	30
26	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. RSC Advances, 2019, 9, 28961-28986.	1.7	42
27	Design, synthesis, and biologic evaluation of novel galloyl derivatives as <scp>HIV</scp>â€1 <scp>RN</scp>ase H inhibitors. Chemical Biology and Drug Design, 2019, 93, 582-589.	1.5	14
28	Identification of Dihydrofuro[3,4-d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. Journal of Medicinal Chemistry, 2019, 62, 1484-1501.	2.9	70
29	Discovery and synthesis of novel beesioside I derivatives with potent anti-HIV activity. European Journal of Medicinal Chemistry, 2019, 166, 159-166.	2.6	8
30	Terpenes from Euphorbia antiquorum and Their in Vitro Antiâ€<scp>HIV</scp> Activity. Chemistry and Biodiversity, 2018, 15, e1700560.	1.0	17
31	Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor. ACS Medicinal Chemistry Letters, 2018, 9, 268-273.	1.3	23
32	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	2.6	68
33	Diterpenes from the stem bark of Euphorbia neriifolia and their inÂvitro anti-HIV activity. Phytochemistry, 2018, 145, 40-47.	1.4	47
34	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. European Journal of Medicinal Chemistry, 2018, 158, 478-492.	2.6	51
35	Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. European Journal of Medicinal Chemistry, 2018, 156, 618-627.	2.6	36
36	Kleinhospitine E and Cycloartane Triterpenoids from Kleinhovia hospita. Journal of Natural Products, 2018, 81, 1619-1627.	1.5	17

#	Article	IF	Citations
37	Role of Porphyromonas gingivalis outer membrane vesicles in oral mucosal transmission of HIV. Scientific Reports, 2018, 8, 8812.	1.6	17
38	Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2788-2792.	1.0	2
39	Structure Optimization of Aloperine Derivatives as HIV-1 Entry Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 1199-1203.	1.3	16
40	Anti-inflammatory and Anti-HIV Compounds from Swertia bimaculata. Planta Medica, 2017, 83, 1368-1373.	0.7	18
41	Two Small Molecules Block Oral Epithelial Cell Invasion by Porphyromons gingivalis. PLoS ONE, 2016, 11, e0149618.	1.1	10
42	Two new ursane-type triterpenoid saponins from Elsholtzia bodinieri. Archives of Pharmacal Research, 2016, 39, 771-777.	2.7	8
43	Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. Journal of Medicinal Chemistry, 2016, 59, 3689-3704.	2.9	31
44	Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. Journal of Medicinal Chemistry, 2016, 59, 9262-9268.	2.9	38
45	Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 240-244.	1.3	61
46	Carolignans from the Aerial Parts of Euphorbia sikkimensis and Their Anti-HIV Activity. Journal of Natural Products, 2016, 79, 578-583.	1.5	35
47	Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 68-71.	1.0	32
48	Fimbriaeâ€mediated outer membrane vesicle production and invasion of <scp>P</scp>orphyromonas gingivalis. MicrobiologyOpen, 2015, 4, 53-65.	1.2	74
49	Flavonoids Isolated from Heatâ€Processed Epimedium koreanum and Their Antiâ€HIVâ€1 Activities. Helvetica Chimica Acta, 2015, 98, 1177-1187.	1.0	14
50	Functional Advantages of Porphyromonas gingivalis Vesicles. PLoS ONE, 2015, 10, e0123448.	1.1	118
51	Stelleralides Dâ€"J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme. Journal of Natural Products, 2015, 78, 2712-2718.	1.5	38
52	Phenolic Diterpenoid Derivatives as Anti-Influenza A Virus Agents. ACS Medicinal Chemistry Letters, 2015, 6, 355-358.	1.3	19
53	Discovery of novel non-covalent inhibitors selective to the Î²5-subunit of the human 20S proteasome. European Journal of Medicinal Chemistry, 2015, 98, 61-68.	2.6	7
54	Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C Î². Journal of Medicinal Chemistry, 2015, 58, 8638-8646.	2.9	35

#	Article	IF	Citations
55	Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. MedChemComm, 2015, 6, 444-454.	3.5	8
56	Inhibitory Effect of b-AP15 on the 20S Proteasome. Biomolecules, 2014, 4, 931-939.	1.8	1
57	Identification and Synthesis of Quinolizidines with Anti-Influenza A Virus Activity. ACS Medicinal Chemistry Letters, 2014, 5, 942-946.	1.3	50
58	New Betulinic Acid Derivatives for Bevirimat-Resistant Human Immunodeficiency Virus Type-1. Journal of Medicinal Chemistry, 2013, 56, 2029-2037.	2.9	69
59	Isolation, Structure Determination, and Anti-HIV Evaluation of Tigliane-Type Diterpenes and Biflavonoid from Stellera chamaejasme. Journal of Natural Products, 2013, 76, 852-857.	1.5	51
60	Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators. ACS Medicinal Chemistry Letters, 2012, 3, 925-930.	1.3	10
61	Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5190-5194.	1.0	33
62	Anti-AIDS Agents 90. Novel C-28 Modified Bevirimat Analogues as Potent HIV Maturation Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 8128-8136.	2.9	54
63	Oxathiazole-2-one derivative of bortezomib: Synthesis, stability and proteasome inhibition activity. MedChemComm, 2011, 2, 1083.	3.5	4
64	Stelleralides Aâ€“C, Novel Potent Anti-HIV Daphnane-Type Diterpenoids from Stellera chamaejasme L.. Organic Letters, 2011, 13, 2904-2907.	2.4	78
65	Picomolar Dichotomous Activity of Gnidimacrin Against HIV-1. PLoS ONE, 2011, 6, e26677.	1.1	33
66	New betulinic acid derivatives as potent proteasome inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5944-5947.	1.0	38
67	Synthesis and proteasome inhibition of lithocholic acid derivatives. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1926-1928.	1.0	14
68	The Role of Dynamin in HIV Type 1 Env-Mediated Cellâ€“Cell Fusion. AIDS Research and Human Retroviruses, 2011, 27, 1013-1017.	0.5	6
69	Proteasome Regulators: Activators and Inhibitors. Current Medicinal Chemistry, 2009, 16, 931-939.	1.2	96
70	Anti-AIDS Agents. 78. Design, Synthesis, Metabolic Stability Assessment, and Antiviral Evaluation of Novel Betulinic Acid Derivatives as Potent Anti-Human Immunodeficiency Virus (HIV) Agents. Journal of Medicinal Chemistry, 2009, 52, 3248-3258.	2.9	72
71	Betulinic Acid Derivatives as Human Immunodeficiency Virus Type 2 (HIV-2) Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 7887-7891.	2.9	49
72	Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 6696-6701.	1.4	32

#	Article	IF	Citations
73	Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 2008, 52, 128-136.	1.4	39
74	Induction of a Nonproductive Conformational Change in gp120 by a Small Molecule HIV Type 1 Entry Inhibitor. AIDS Research and Human Retroviruses, 2007, 23, 28-32.	0.5	14
75	Activation and inhibition of the proteasome by betulinic acid and its derivatives. FEBS Letters, 2007, 581, 4955-4959.	1.3	87
76	Anti-AIDS Agents 69. Moronic Acid and Other Triterpene Derivatives as Novel Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 2006, 49, 5462-5469.	2.9	113
77	Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. Bioorganic and Medicinal Chemistry, 2006, 14, 2279-2289.	1.4	76
78	Inhibition of Human Immunodeficiency Virus Type 1 Entry by a Binding Domain of Porphyromonas gingivalis Gingipain. Antimicrobial Agents and Chemotherapy, 2006, 50, 3070-3074.	1.4	15
79	Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. Virology, 2005, 332, 623-628.	1.1	66
80	Betulinic acid derivatives as HIV-1 antivirals. Trends in Molecular Medicine, 2005, 11, 31-36.	3.5	166
81	The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. Expert Opinion on Investigational Drugs, 2005, 14, 681-693.	1.9	45
82	Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation. Journal of Virology, 2004, 78, 922-929.	1.5	173
83	Bifunctional Anti-Human Immunodeficiency Virus Type 1 Small Molecules with Two Novel Mechanisms of Action. Antimicrobial Agents and Chemotherapy, 2004, 48, 663-665.	1.4	47
84	Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology, 2004, 324, 525-530.	1.1	19
85	The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology, 2004, 1, 15.	0.9	68
86	Neutralization epitopes of the HIV-1 primary isolate DH012. Vaccine, 2003, 21, 3301-3306.	1.7	5
87	Anti-AIDS Agents 49.1Synthesis, Anti-HIV, and Anti-Fusion Activities of IC9564 Analogues Based on Betulinic Acid. Journal of Medicinal Chemistry, 2002, 45, 4271-4275.	2.9	75
88	Molecular Targets of Anti-HIV-1 Triterpenes. Current Drug Targets Infectious Disorders, 2002, 2, 33-36.	2.1	35
89	Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. Antimicrobial Agents and Chemotherapy, 2001, 45, 60-66.	1.4	88
90	Monoclonal Antibodies That Bind to the Core of Fusion-Active Glycoprotein 41. AIDS Research and Human Retroviruses, 2000, 16, 2037-2041.	0.5	17

#	Article	IF	Citations
91	Anti-AIDS Agents. 34.â€Synthesis and Structureâ^'Activity Relationships of Betulin Derivatives as Anti-HIV Agents. Journal of Medicinal Chemistry, 1998, 41, 4648-4657.	2.9	139
92	Anti-AIDS agentsâ€"XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorganic and Medicinal Chemistry, 1997, 5, 2133-2143.	1.4	108
93	Noncytolytic CD8 T cell-mediated suppression of HIV replication. Seminars in Immunopathology, 1997, 18, 355-369.	4.0	14
94	Betulinic Acid and Dihydrobetulinic Acid Derivatives as Potent Anti-HIV Agents1. Journal of Medicinal Chemistry, 1996, 39, 1016-1017.	2.9	262
95	Oligoclonal CD8 Lymphocytes from Persons with Asymptomatic Human Immunodeficiency Virus (HIV) Type 1 Infection Inhibit DIV-1 Replication. Journal of Infectious Diseases, 1995, 172, 964-973.	1.9	49
96	Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding. Immunological Reviews, 1994, 140, 93-104.	2.8	79